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ABSTRACT
Background. Pressurized intraperitoneal aerosol chemo-
therapy (PIPAC) is a novel approach for treating peritoneal
carcinomatosis. First encouraging results have been
obtained in human patients. However, delivering chemo-
therapy as an aerosol might result in an increased risk of
exposure to health care workers, as compared with other
administration routes.
Methods. PIPAC was applied in two human patients using
chemotherapeutic drugs (doxorubicin and cisplatin), and
air contamination levels were measured under real clinical
conditions. Air was collected on a cellulose nitrate filter
with a flow of 22.5 m3/h. To exclude any risk for health
care workers, both procedures were remote controlled.
Toxicological research of cisplatin was performed
according to NIOSH 7300 protocol. Sampling and analysis
were performed by an independent certification
organization.
Results. The following safety measures were imple-
mented: closed abdomen, laminar airflow, controlled
aerosol waste, and protection curtain. No cisplatin was
detected in the air (detection limit \ 0.000009 mg/m3) at
the working positions of the surgeon and the anesthesiol-
ogist under real PIPAC conditions.
Conclusions. For the drugs tested, PIPAC is in compli-
ance with European Community working safety law and
regulations. Workplace contamination remains below the
tolerance margin. The safety measures and conditions as
defined above are sufficient. Further protecting devices,
such as particulate (air purifying) masks, are not necessary.
PIPAC can be used safely in the clinical setting if the
conditions specified above are met. However, a toxico-
logical workplace analysis must be performed to confirm
that the procedure as implemented complies with local
regulations.
Local drug administration has been used as a therapeutic
modality for many years and for a broad spectrum of
indications. In particular, intraperitoneal chemotherapy
(IPC) is increasingly used in clinical practice. The goal of
IPC is to increase drug exposure of cancer cells within the
peritoneal cavity while minimizing systemic toxicity.1
Intraperitoneally administered drugs are expected to pen-
etrate directly into the peritoneal nodules, resulting in a
high locoregional bioavailability.2 For example, during
hyperthermic intraperitoneal chemotherapy (HIPEC), a
high dose of chemotherapeutic solution is administered
directly into the abdominal cavity, in most cases into the
open abdomen, at a temperature of approximately
42.5–43 C. For multiple indications, HIPEC has been
shown to be associated with prolonged survival compared
to systemic chemotherapy alone.3
However, IPC has two major limitations. First, there is a
limited depth of drug penetration into the tissue. The lim-
ited tissue penetration leads to a rapid drop in drug
concentration below the level needed to destroy tumor
cells.4 Second, much of the residual tumor burden is
untreated or undertreated because peritoneal exposure to
chemotherapy is poor.
Pressurized intraperitoneal aerosol chemotherapy (PI-
PAC) is a novel approach that overcomes several
limitations of the more conventional IPC method. PIPAC is
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a particular application of the general principle of thera-
peutic capnoperitoneum and of aerosolized
chemotherapy.5,6 Instead of distributing the chemothera-
peutic substance in the form of a liquid solution into the
abdomen, the drug is nebulized with carbon dioxide to
create an aerosol. Aerosols consist of two phases: a liquid
phase (droplets) and a gaseous phase. According to phys-
ical laws, if the size of droplets is small, aerosols behave
like a gas. Because a gas distributes homogeneously within
a closed space, the drug concentration is expected to be
equal within the whole abdominal cavity.
As a second difference between PIPAC versus IPC, the
aerosol is applied within the pressurized abdominal cavity
so that a pressure gradient is artificially generated between
the intraperitoneal and the extraperitoneal space. As a
direct consequence, diffusion of liquids and substances
through the peritoneum is enhanced. Moreover, the applied
intraperitoneal pressure compensates for the interstitial
fluid pressure, which impairs drug uptake into solid tumors
and contributes to chemotherapy resistance.7
Theoretically, both the more even distribution of che-
motherapeutic agents within the abdominal cavity and the
improved tissue penetration of drugs provide new thera-
peutic opportunities to increase the efficacy of
intraperitoneally applied chemotherapy. This hypothesis
has been confirmed in a rodent model: when intra-
abdominal pressure was raised, increased intratumoral drug
concentration and enhanced tumor cell death with doxo-
rubicin and cisplatin were observed.8,9 We have made
similar observations in the large animal model as well as in
human specimens ex vivo.5,10 Treating peritoneal diseases
with aerosolized drugs has a number of advantages. First,
aerosolized chemotherapy provides a direct, minimally
invasive means for targeted delivery to different regions of
the peritoneum. Second, this route of administration
delivers a high dose to the target site. Third, aerosolized
IPC causes fewer adverse effects than intravenous admin-
istration. Thus, PIPAC opens new avenues in the therapy of
peritoneal carcinomatosis, an unmet medical need.11
However, delivering chemotherapy as an aerosol might
cause an increased risk of exposure to health care workers
compared to other administration routes. This is due to the
difficulty of controlling the spread of aerosols during PI-
PAC, which in turn contributes to the risk of leakage and
unwanted exposition.
To prevent any harm to health care workers, we have
identified and evaluated potential hazards concerning
occupational exposures during PIPAC performance. In a
second set of experiments, we have simulated PIPAC in the
laboratory and in the operating room (OR). In addition, we
have applied PIPAC in the human patient using chemo-
therapeutic drugs and measured contamination levels under
real clinical conditions.
METHODS
Ethical, Legal, and Regulatory Background
The study protocol was submitted to the institutional
review board (IRB; Common Ethics Committee of the
Westfalian Wilhelms-University Mu¨nster and of the
Westfalian Medical Chamber). The IRB recommended
performing the first PIPAC therapy with volunteers, which
were extensively informed and trained in the PIPAC
procedure.
Methodology
The following steps were defined: identification of
hazardous substances and dose; identification of possible
exposure ways; simulation of the PIPAC procedure with
nontoxic aerosols and smoke; redaction of standard oper-
ating procedures (SOP); second simulation according to the
SOP; informing and training the health care workers; and
performance of the first two PIPAC procedures with che-
motherapeutic substances and workplace measurements
under real conditions.
Nebulizer
The nebulizer (Reger Medizintechnik, Rottweil, Ger-
many) has been described elsewhere .5 In brief, it consists
of several components, including an injector, a tube, and a
nozzle. The nozzle has a diameter of 0.2 mm. A pressure of
up to 20 bar is delivered upstream of the nozzle, using an
industry-standard contrast medium injector (Injektron
82 M, MedTron, Saarbru¨cken, Germany, including a
remote control device, MT1130/1).
Operating Room Characteristics
The PIPAC procedure was performed within an OR
equipped with laminar airflow. Volume of the OR was
approximately 168 m3. Air flow was 1.8 9 106 L/h. Room
temperature was 22.3–22.6 C. Relative humidity was
36–37 %. Atmospheric pressure was 994 hPa. Vacuum
was generated with a pressure of -0.85 bar (Dra¨ger,
Lu¨beck, Germany).
Assumptions
The assumptions for the determination of exposure are
listed in Table 1.
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Chemotherapy
We have focused on the application of two chemother-
apeutic agents: cisplatin and doxorubicin. Chemotherapy
was applied as follows: nebulization over 3–6 min of
7.5 mg cisplatin/m2 body surface followed immediately by
the nebulization of 1.5 mg doxorubicin/m2 body surface
into the abdominal cavity filled with CO2 at a pressure of
16–20 mbar (12–15 mm Hg) at a temperature of 37 C
followed by 30 min steady-state before exsufflation.
Experimental Protocol
Two PIPAC procedures were performed in two con-
secutive patients within the same OR. Between the
procedures, the room was cleaned according to the hospi-
tal’s standard hygiene and surface cleaning protocols.
Each procedure was structured into four consecutive
phases, as follows:
• Phase 1: CO2 insufflation is provided over an industry-
standard trocar (Kii Access System, Applied Medical,
Darmstadt, Germany), with a target pressure of
16 mbar (12 mm Hg). The access system was secured
with an intra-abdominal balloon and an extra-abdom-
inal obturator, ensuring tightness of the abdomen and
steadiness of the pressure. Two 5-mm working trocars
are inserted.
• Phase 2: A nebulizer (MIP, Reger Medizintechnik,
Rottweil, Germany) was introduced through the access
trocar and aerosol formation of the chemotherapy
solution into the abdominal cavity using the injector
over.
• Phase 3: The system was kept in steady state for 30 min
at a constant pressure and temperature. The abdomen
was hermetically sealed; the total gas flow was
minimal.
• Phase 4: At the end of the procedure, the gas from the
abdomen was released directly into the hospital’s
waste-air system over one of the trocars and an
aerosol/smoke filter (pores 0.027 lm, model
03110-10, mtp, Neuhausenob Eck, Germany).
Toxicology Analysis
The probe sampling system used was a Gravikon VC25
device combined with a dust detector (Stro¨hlein, Kaarst,
Germany). Air was collected on a cellulose nitrate filter
with a diameter of 50 mm, with a flow of 22.5 m3/h.
Toxicological research analysis of cisplatin levels was
performed according to a standard protocol (NIOSH 7300).
The detection limit was 0.3 lg/sample. Sampling and
analysis were performed by engineers of the Division for
Hazardous Substances at the Laboratory for Environmental
and Product Analysis of DEKRA Industrial GmbH in
Stuttgart (Germany), an independent certification
organization.
RESULTS
Identification of Hazardous Substances and Dose
The toxicological characteristics of cisplatin and doxo-
rubicin are summarized in Table 2. In short, cisplatin is
highly poisonous. It can provoke anaphylactic reactions
and it irritates the eyes and skin; it has no transdermal
absorption. Furthermore, it irritates airways and has a
cumulative toxic effect on kidney, bone marrow, and the
inner ear. It is probably carcinogenic to humans. Doxoru-
bicin is hazardous to human health by provoking mucosal
inflammation, leucopenia, and dilative cardiomyopathy.
Additionally, it induces DNA mutation and is carcinogenic
to humans. The total dose applied during PIPAC is
approximately 10 % of a usual systemic chemotherapy
dose. There is no legal exposure limit for either of these
two substances in Germany. However, in the Netherlands,
the maximally allowed air concentration for cisplatin is
\0.00005 mg/m3.
Identification of Possible Mean of Exposure
The preparation of the chemotherapeutic agents in the
hospital pharmacy and their transport in adequate con-
tainers to the OR is scheduled according to the German
recommendations.12 Both agents are provided in a closed
TABLE 1 Assumptions for determination of exposure
Parameter Value
Room temperature 22 C
Inhalation rate 1.5 m3/h
Body weight 70 kg
Body surface 1.7 m2
Duration of therapy 30–60 min per application; 1 therapy
per day
Total amount of applied
CO2
3 to max. 6 L
Duration of exposure
(presence of OR team)
No routine presence; if intervention
required, max. 20 min per procedure
Technical details of
application
Pressure in injector: 0.8 bar
Pressure at the nozzle: 0 bar
Duration of nebulizing: *5 min
Total applied volume: 150 ml per
chemotherapeutic cycle
Diameter of nozzle: 0.2 mm
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delivery system (special injection syringes filled with NaCl
0.9 % solution). Identified exposure ways are ocular, der-
mal, and inhalative exposition. Other possibilities were
reasonably excluded.
First PIPAC Simulation with NaCl 0.9 % Solution
Before performing the first clinical PIPAC application,
the procedure was simulated in the OR using a laparoscopy
TABLE 2 Safety data for cisplatin and doxorubicin
Parameter Cisplatin Doxorubicin
CAS-/EG no. 15663-27-1/239-733-8 23214-92-8/245-495-6
25316-40-9/246-818-3 (hydrochloride)
Formula
Molecular weight 300.06 g/mol 543.52 g/mol
Melting point 270 C; dark yellow powder at room temperature 205 C (degradation); crystalline red powder at room
temperature
Boiling point Not applicable Not applicable
Steam pressure Not applicable Not applicable
Water solubility 2.530 g/L (25 C) 0.0928 g/L (25 C)
LD50 oral 20 mg/kg (rat) 570 mg/kg (mouse)
32 mg/kg (mouse) –
NOAEL No data No data
Important toxicological
details
Acute toxicity: very toxic
Skin and eye irritation
No evidence for transdermal absorption
Cumulative damage of kidney, bone marrow, and inner
ear
No evidence of carcinogenicity in human
Evidence for carcinogenicity and teratogenicity in
mouse and rat
Level of carcinogenicity: 2A
Anaphylactic reactions reported





Evidence for carcinogenicity in animals
Evidence for mutagenicity in animals
Level of carcinogenicity 2A
Total amount applied 15 mg in 150 ml NaCl 0.9 % 3 mg in 150 ml NaCl 0.9 % solution
Concentration of applied
solution
0.1 mg/ml = 0.1 g/L = 0.01 % 0.02 mg/ml = 0.02 g/L = 0.002 %
Workplace exposure limits Germany: not available Germany no upper legal limit
Netherlands: 0.00005 mg/m3 –
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training phantom and NaCl 0.9 % aerosol. Working steps
were written down, and risk analysis was performed within
an interdisciplinary team including physicians (surgeons
and anesthesiologists), scrub nurses, hospital technicians,
nebulizer engineers, and occupational health experts. Pos-
sible mechanical failures related to the injector, the
infusion tube, the nebulizer itself, the laminar flow system,
and the tightness of the abdomen were identified. In case of
any failure of the procedure, appropriate security measures
were taken and defined. A standard operating protocol was
thus established that served as a basis for the second
simulation.
Second PIPAC Simulation with Smoke and Artificial
Leak
The second simulation was performed in the OR under
strict implementation of the SOP simulating the abdomen
with a sealed plastic container of similar dimensions. An
aerosol of CO2 and smoke with the same pressure as during
laparoscopy (using identical, industry-standard technical
instruments, such as access trocars, video camera, grasping
forceps) was applied. We were able to perform the com-
plete procedure without any incident; in particular, the
system remained tight. Then a maximal leakage (an access
trocar was fully opened) was simulated. The smoke
escaping from the leak was flowing downward (Fig. 1) to
the floor and into the lateral outflow windows of the hos-
pital air-waste system.
Information and Training of the Team of Volunteers
On the basis of the successful simulations, it was deci-
ded to schedule two patients for the first PIPAC
procedures. Informational meetings allowing open, inter-
active discussion were organized because the planned
procedures raised emotional concerns, in particular among
scrub nurses and cleaning workers. On the basis of these
discussions, we decided to restrict the first procedure to
volunteers within the framework of a special shift that
excluded other simultaneous surgical procedures. Before
the first procedure, the team of volunteers received inter-
disciplinary training according to the SOP.
Performance of First PIPAC Procedures
with Chemotherapy
The first PIPAC procedure was performed on November
5, 2011, under the supervision of a safety officer and
included workplace air measurements. The SOP were
strictly implemented; in particular, nobody remained
within the OR during the PIPAC procedure, which was
remote controlled. The nebulizer functioned as expected,
and the system remained airtight (Fig. 2). At the end of the
procedure, the chemotherapy aerosol was exhausted into
the air-waste system of the hospital and released into the
environment.
Air Contamination of the Operating Room
with Cisplatin
Air was sampled during two consecutive PIPAC pro-
cedures (Fig. 3). Results are summarized in Table 3. Air
analysis revealed no traces of cisplatin, either at the posi-
tion of the surgeon or the anesthesiologist.
Conclusions
Chemotherapy is an essential component of modern
multimodal cancer therapy. However, many drugs used to
fight cancer are mutagenic, teratogenic, and carcinogenic in
experimental systems.
Development of PIPAC has raised concerns about the risk
of occupational inhalation linked to the application of toxic
aerosols. To assess this problem, it was not possible to rely
on existing safety standards because PIPAC had never yet
been performed. However, we could compare—to some
extent—intraperitoneal aerosol chemotherapy to aerosol-
ized chemotherapy in lung cancer. In this latter setting,
aerosolized chemotherapy has been delivered in a well-
ventilated room with an air-filtering system.13 Alternatively,
a mobile-filter air-cleaning system combined with a col-
lecting tent was also effective in preventing propagation of
aerosol during inhalation of nebulized liposomal cisplatin.14
Chemotherapy levels in the air were below workplace
exposure limits. Other recent phase 1 studies have demon-
strated the feasibility and safety of aerosol delivery of
doxorubicin and gemcitabine in lung cancer patients.14,15
In occupational settings, environmental monitoring of
exposure to toxic aerosols seems to be superior to biological
monitoring. It offers the possibility of simultaneous deter-
mination of components of mixtures, is simple to interpret,
and evaluates short-term exposure to environmental irri-
tants.16 Thus, estimation of exposure under real conditions
was an important step to provide a safe working environ-
ment during PIPAC. The total chemotherapy dose was 1:10
of a systemic dose delivered intravenously. The aerosol was
applied within the closed abdomen, and no leakage occur-
red. No cisplatin contamination in the air was detected.
Because PIPAC is applied within a closed system, the
risk of skin contamination with chemotherapy is also
minimal (e.g., after a manipulation error with the contrast
medium injector, or use of inadequate, low-pressure infu-
sion tubing). This risk can be reduced by providing one-
block systems (nebulizer and infusion tubing), and by
training and drilling in order to minimize human errors. In
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the case of leakage, skin contamination with chemotherapy
solutions would be adequately met by wearing special
chemotherapy gloves and protective glasses. A special set
of gloves used to remove spilled chemotherapy solution is
available on the OR. The OR has to be cleaned afterward,
as it is routinely the case because of biological risks such as
blood contamination. Tissues, tubes, lines, and other
devices such as operation drapes and sponges have to be
disposed into special sealed, labeled containers.
In summary, this study shows that the risk of occupa-
tional exposure to chemotherapy during PIPAC has been
reduced to a minimum so that the procedure complies with
German occupational safety regulations. This is an
important precondition for beginning phase 2 and phase 3
clinical studies in order to define the possibilities and limits
of PIPAC in the therapy of peritoneal carcinomatosis. Strict
application of the SOP, repeated measurement of exposure
levels, and continuous education of physicians and nurses
FIG. 1 PIPAC simulation with smoke
and artificial leakage. Sealing access
trocars (a) were introduced into a sealed
plastic box (b) with the same volume
dimensions as the human abdominal
cavity. The box was pressurized with
CO2 and steam. Via an artificial leakage
(open access trocar), the steam (white
bold arrows) was observed to be
directed to the floor and not randomly
distributed within the OR. This is
caused by the laminar air flowing
downward from the ceiling to the floor
FIG. 2 First PIPAC under real
conditions. Access trocars (a) with the
nebulizer (b) in situ. The
chemotherapeutic agents were
transported from the injector to the
nebulizer via a high-pressure infusion
line (c). CO2 was injected into the
abdominal cavity via a standard gas line
(d) and the trocar (e) (camera trocar).
At the end of the procedure, the
chemotherapeutic capnoperitoneum
was desufflated via line (f) over an
aerosol filter into the air-waste system
of the hospital. Dark arrows indicate
the flow direction of the gas and
chemotherapeutics. Asterisk Trocar
sealing rings
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will be necessary with the increasing use of this new
therapeutic strategy in order to avoid any harm.
After the implementation of all equipment, organiza-
tional aspects, and procedures as described above, any
other team starting PIPAC should perform a toxicological
workplace analysis. This analysis must to be scheduled
before the routine application of PIPAC to ensure that it
can be performed in accordance with local regulations.
WHAT THIS STUDY ADDS
It is possible to apply a therapeutic pressurized chemo-
therapy aerosol into the abdominal cavity of peritoneal
carcinomatosis patients without occupational health hazards.
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